A recent pooled analysis of the two previously described phase 3 studies, highlighted the long-term benefits of first-line treatment with nivolumab plus ipilimumab, with or without two cycles of chemotherapy, compared to chemotherapy alone in patients with metastatic NSCLC and low PD-L1 expression (<1%). Here, CD274 is linked to non-small cell lung carcinoma.